These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11479629)

  • 1. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
    Ichikawa K; Liu W; Zhao L; Wang Z; Liu D; Ohtsuka T; Zhang H; Mountz JD; Koopman WJ; Kimberly RP; Zhou T
    Nat Med; 2001 Aug; 7(8):954-60. PubMed ID: 11479629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
    Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
    Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
    Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
    Mori E; Thomas M; Motoki K; Kataika S
    FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.
    Higuchi H; Bronk SF; Taniai M; Canbay A; Gores GJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):461-7. PubMed ID: 12388624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
    Ishikawa E; Nakazawa M; Yoshinari M; Minami M
    J Virol; 2005 Jun; 79(12):7658-63. PubMed ID: 15919918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
    Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
    Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
    Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
    Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells].
    Ma YF; Zhang J; Zhao YP; Yang DL; Chen YH
    Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):528-30. PubMed ID: 15555281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of established tumors in mice by a combination antibody-based therapy.
    Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
    Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway.
    He Q; Lee DI; Rong R; Yu M; Luo X; Klein M; El-Deiry WS; Huang Y; Hussain A; Sheikh MS
    Oncogene; 2002 Apr; 21(17):2623-33. PubMed ID: 11965535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.
    Hao C; Song JH; Hsi B; Lewis J; Song DK; Petruk KC; Tyrrell DL; Kneteman NM
    Cancer Res; 2004 Dec; 64(23):8502-6. PubMed ID: 15574753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.